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AbstrAct
Radiation therapy is an effective cancer treatment modality although tumors 
invariably become resistant. Using the transgenic adenocarcinoma of mouse prostate 
(TRAMP) model system, we report that a hypofractionated radiation schedule (10 
Gy/day for 5 consecutive days) effectively blocks prostate tumor growth in wild type 
(β1wt /TRAMP) mice as well as in mice carrying a conditional ablation of β1 integrins in 
the prostatic epithelium (β1pc-/- /TRAMP). Since JNK is known to be suppressed by β1 
integrins and mediates radiation-induced apoptosis, we tested the effect of SP600125, 
an inhibitor of c-Jun amino-terminal kinase (JNK) in the TRAMP model system. Our 
results show that SP600125 negates the effect of radiation on tumor growth in β1pc-/- /
TRAMP mice and leads to invasive adenocarcinoma. These effects are associated with 
increased focal adhesion kinase (FAK) expression and phosphorylation in prostate 
tumors in β1pc-/- /TRAMP mice. In marked contrast, radiation-induced tumor growth 
suppression, FAK expression and phosphorylation are not altered by SP600125 
treatment of β1wt /TRAMP mice. Furthermore, we have reported earlier that abrogation 
of insulin-like growth factor receptor (IGF-IR) in prostate cancer cells enhances the 
sensitivity to radiation. Here we further explore the β1/IGF-IR crosstalk and report 
that β1 integrins promote cell proliferation partly by enhancing the expression of 
IGF-IR. In conclusion, we demonstrate that β1 integrin-mediated inhibition of JNK 
signaling modulates tumor growth rate upon hypofractionated radiation.
IntroductIon
Integrin-mediated adhesion of cancer cells to the 
extracellular matrix regulates the cellular response to 
ionizing radiation [1-3]. Our laboratory and others have 
shown that integrins regulate the response to radiation 
by modulating the activity of c-Jun NH2-terminal kinase 
(JNK) [3-5], a member of the MAPK family, also known 
as stress-activated protein kinase [6]. Integrin regulation 
of JNK signaling is complex; JNK has been shown to be 
either activated by β1 or αv integrins in head and neck 
[4] and in nasopharyngeal cancer [5] or suppressed by β1 
integrins in prostate cancer as reported in our in vivo study 
[3]. 
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While recent advances in radiotherapy have 
enabled precise targeting of tumor tissue, recurrence 
after radiotherapy, however, remains a concern. Many 
factors may lead to the failure of radiotherapy and to 
recurrence (Reviewed in [7]) including enhanced DNA 
repair, activation of tumor cell survival pathways, 
and inhibition of programmed cell death as well as the 
presence of a subpopulation of cancer stem cells that 
are inherently resistant to radiation (Reviewed in [8]). 
The conventional external beam radiation therapy used 
in the clinic ranges from 75.6 to 81.0 Gy of radiation 
divided into 1.8- to 2.0 Gy fractions, and is carried out 
daily between 7 and 9 weeks (Reviewed in [9]). Recently, 
moderate (<35 fractions) and extreme (<5 fractions) 
hypofractionated radiation therapy has been reported to 
yield more favorable results than conventional regimens 
(2 Gy/fraction), both in terms of biochemical response 
and toxicity [10]. However, there is no consensus in 
the scientific community whether hypofractionated 
radiation significantly reduces biochemical and/or 
clinical disease failure [11]. Thus, in the current study, 
we have investigated the effect of hypofractionated high 
dose radiation administered at shorter intervals (mice 
are irradiated with a total dose of 50 Gy, carried out in 
fractionated doses of 10 Gy, consecutively for 5 days). 
This simulates the approach proposed for clinical use in an 
effort to alleviate patient inconvenience and reduce health 
care costs (Reviewed in [9]). An improved understanding 
of the mechanisms involved in radiation-induced tumor 
regression may ultimately provide novel strategies of 
intervention in the treatment of human malignancies.
Using this hypofractionated radiation approach, we 
have tested the effect of a JNK inhibitor SP600125 (SP) 
on radiation response in wild type (β1wt /TRAMP) mice 
as well as in mice carrying a conditional ablation of β1 
integrins in the prostatic epithelium (β1pc-/- /TRAMP). 
SP is a reversible ATP-competitive inhibitor of JNK that 
blocks all three JNK isoforms with similar potency [12]. 
Its specificity is attributed to the fact that it effectively 
occupies the hydrophobic pocket of the ATP binding site 
in JNK1 and variations of crucial hydrophobic residues 
in other MAP kinases make JNK a selective target [13]. 
SP has been reported to be a selective JNK inhibitor [14] 
and its effectiveness against JNK in vivo has been widely 
reported [15-18]. 
In the present study, we demonstrate that the 
effects of JNK inhibition are contingent upon β1 
integrin expression. We studied the signaling interface 
between β1 integrins and the type-1 insulin-like growth 
factor receptor (IGF-IR), a trans-membrane tyrosine-
kinase receptor, known to play an essential role in the 
development and progression of cancer by regulating cell 
proliferation, differentiation, apoptosis and metastasis 
[19]. Like β1 integrins, IGF-IR signaling has been 
reported to mediate resistance to radiotherapy [20, 21]. 
Together, these receptors play a concerted role in radio-
resistance of cancer cells [3] and unraveling the nature 
of these interactions is expected to contribute not only to 
understanding the mechanisms of resistance, but also in 
the identification of novel therapeutic targets.
Here, we have studied β1-mediated downstream 
signaling in vivo in prostate cancer resistance to 
hypofractionated radiation. We report that JNK inhibition 
compromises the beneficial effects of radiation therapy in 
TRAMP mice carrying conditional ablation of β1 (β1pc-/- /
TRAMP), and results in a significant increase in prostate 
tumor growth associated with increased FAK expression 
and activity in these tumors. 
results
JNK inhibition in β1pc-/- trAMP mice irradiated 
in the lower pelvis leads to prostate cancer 
progression
We have previously demonstrated that conditional 
ablation of β1 integrins significantly improves survival 
and delays prostate cancer progression in response to 
lower pelvis irradiation in TRAMP mice [3]. To assess 
the importance of JNK activation in response to radiation, 
20 week-old β1pc-/- /TRAMP mice were treated with 
hypofractionated radiation regimen that consisted of 
10 Gy fractions for 5 consecutive days (total 50 Gy). 
In conjunction with radiation treatment, intraperitoneal 
(IP) injections of SP and PPCES (PP) were administered 
three times/week and were continued for 9 additional 
weeks followed by euthanasia at 35 weeks of age. This 
irradiation strategy led to effective tumor suppression 
in β1pc-/- /TRAMP mice. JNK inhibition in these mice 
markedly compromises the effect of radiation and results 
in increased tumor load at the end of the treatment 
period. Histopathological analysis of prostate tissues 
from irradiated β1pc-/- /TRAMP mice treated with SP 
consistently reveals aggressive pathological characteristics 
when compared to controls injected with PP which show 
in situ carcinoma characterized by marked papillary and 
cribriform epithelial proliferation with acinar expansion 
(Figure 1A, left panels). High magnification images of 
prostate tissues from SP-treated mice (Figure 1A, right 
panel) specifically reveal invasive carcinoma composed 
of anaplastic epithelioid cells growing in sheets and 
nests. Individual cells show marked cytologic dysplasia 
and areas of tissue necrosis within the expanded acini. 
Analysis of total tumor mass in irradiated mice injected 
with either PP (n = 13) or SP (n = 17) indicates that SP 
treatment significantly increases tumor mass in β1pc-
/- /TRAMP mice, P < 0.0001 (Figure 1B). These results 
suggest that the therapeutic effect of β1 abrogation in 
response to irradiation is offset by JNK inhibition. 
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Figure 1: JNK inhibition counteracts the effect of irradiation and supports aggressive prostate growth in β1pc-/- trAMP 
mice. A. Histopathological analysis after Hematoxylin and Eosin (H&E) staining of prostate tissue from irradiated β1pc-/- /TRAMP mice. 
At the age of 20 weeks, mice were subjected to IP  injections of vehicle PPCES or inhibitor SP600125, administered 3 times/week for 
10 weeks. Two hours after the first IP injection with either PPCES or SP600125, the lower pelvises of the mice were irradiated with a 
hypofractionated radiation regimen that consisted of 10 Gy fractions (total dose 50 Gy) administered for 5 consecutive days. Mice were 
euthanized at 35 weeks of age and prostate tissues were analyzed for tumor progression. Representative H&E images of tissues from control 
or treated mice are shown (left panels). Scale bar 100 µm. The right panel shows representative H&E high magnification images of prostate 
tumors from irradiated and SP600125-treated β1pc-/- /TRAMP mice depicting aggressive histopathology. Scale bar 50 µm. b. The tumor 
mass distribution in irradiated β1pc-/- TRAMP mice injected with PPCES vehicle or SP600125-treated is shown. Median tumor weight with 
interquartile range and individual data points are plotted. PPCES group n = 13 mice, SP600125 group n = 17 mice. A statistically significant 
increase in tumor mass is found in the SP600125-treated cohort as compared to the cohort injected with PPCES. P < 0.0001 (Wilcoxon-
Mann-Whitney two-sided test). 
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JNK inhibition in β1wt /trAMP mice does 
not interfere with radiation-induced tumor 
suppression
Since we have previously demonstrated that β1 
integrins suppress radiation-induced JNK activation [3], 
the JNK inhibitor was not expected to elicit any changes 
upon prostate irradiation in mice expressing wild type β1 
(β1wt /TRAMP). To test whether JNK inhibition influences 
radiation resistance in β1wt /TRAMP prostate, we carried 
out irradiation and PP or SP injections in β1wt /TRAMP 
mice as described above in Figure 1. Histopathological 
analysis of prostate tissues from irradiated β1wt /TRAMP 
mice injected with either PP or SP does not show any 
tumor growth (Figure 2). Prostate tissues from SP-treated 
β1wt mice show marked papillary and cribriform epithelial 
hyperplasia with high-grade dysplasia (Figure 2A, right 
panel). In some glands, the changes are equivalent to 
in situ carcinoma; however, invasive carcinoma is not 
observed in this group. The prostatic tissues from the PP 
group show a spectrum of phenotypes including papillary 
hyperplasia with mild atypia, papillary and cribriform 
hyperplasia with high-grade dysplasia and combined 
epithelial and stromal hyperplasia with minimal cytologic 
atypia (Figure 2A, left panel). The differences in tumor 
mass between PP (n = 15) and SP (n = 14) cohorts are not 
significant, P = 0.41 (Figure 2B). These data imply that 
JNK inhibition does not modify the radiation response in 
β1wt tumors. 
Collectively, these data show that JNK inhibition 
counteracts the effect of radiation therapy in the absence of 
β1 integrins and accelerates tumor growth and progression 
as indicated in our schematic drawing in Figure 3A. This 
is consistent with our earlier findings that JNK activation 
is suppressed by β1 integrins in prostate cancer cells 
[3] and with our new observation that exogenous JNK 
inhibition does not affect tumor growth in β1wt mice. To 
confirm SP-mediated JNK suppression in vivo, prostate 
tissues isolated from irradiated controls (PP cohort) and 
irradiated plus SP-treated β1pc-/- /TRAMP cohort were 
evaluated for JNK function. Our results demonstrate that 
SP significantly blocks the phosphorylation of JNK in 
prostate tissues (Figure 3B). 
JnK inhibition in vivo up-regulates the expression 
and activation of FAK in irradiated β1pc-/- prostate 
tumors
FAK is known to support tumor growth and 
metastasis [22], and in TRAMP mice reportedly 
contributes to the development of neuroendocrine 
carcinoma [23]. Consistent with its role in aggressive 
forms of the disease, FAK signaling has been associated 
with radiation resistance [24]. To investigate if β1 
integrins modulate FAK signaling in the presence of 
radiation, we evaluated FAK expression and activity 
profiles in our model system. Prostate tissues from 
irradiated and SP- treated β1pc-/- /TRAMP mice were 
analyzed for the expression and phosphorylation of 
FAK. Our results demonstrate that JNK inhibition by SP 
selectively leads to the up-regulation of FAK expression 
and phosphorylation (Figure 4A). No changes in AKT 
phosphorylation, however, are observed in these tissues 
(Figure 4B). Consistent with FAK phosphorylation, we 
also observe induction of tyrosine kinase Src expression 
and phosphorylation upon JNK inhibition in tissues from 
β1pc-/- /TRAMP mice (data not shown). In order to study 
the histological localization of FAK, prostate tissues 
from SP-treated β1pc-/- /TRAMP mice were analyzed for 
Figure 2: JNK inhibition in β1wt /trAMP mice does 
not offset the effect of radiation on tumor growth. 
A. Histopathological analysis of irradiated tumors from β1wt /
TRAMP mice treated as described in Figure 1. Representative 
H&E images of tissues from control or treated mice are shown. 
Scale bar 100 µm. b. The tumor mass distribution in lower 
pelvis-irradiated β1wt /TRAMP mice injected with PPCES or 
SP600125 is shown. Median tumor weight and individual data 
points are plotted. PPCES group n = 15 mice, SP600125 group n 
= 14 mice. No statistically significant differences in tumor mass 
are found between SP and vehicle treated β1wt /TRAMP cohorts. 
P = 0.4094 (Wilcoxon-Mann-Whitney two-sided test). 
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Table 1: Expression profile and localization of FAK in prostate tissues from irradiated and/or SP-treated β1pc-/- /
trAMP mice.
Mouse 
number JnK inhibitor Histopathology
FAK intensity FAK Positive 
Fields
[Percentage] nuclear cytoplasmic
1 +  Invasive carcinoma 3 - 100%
2 + Aggressive high grade tumor, neuroendocrine phenotype 3 - 100%
3 + High grade tumor, carcinoma in situ 3 - 100%
4 + High grade tumor 3 - 100%
5 + Carcinoma in situ and high grade PIN 3 - 100%
6 + High grade tumor 3 1 100%
7 + High grade tumor 3 3 100%
8 + Aggressive high grade tumor, high grade PIN, invasive carcinoma, unusual papillary cells 2-3 2-3 90%
9 + High grade aggressive tumor 3 3 80%
10 + High grade tumor 2-3 2-3 80%
11 _ Carcinoma in situ, benign, PIN 1-2 1-2 100%
12 _ Well contained high grade PIN 1-2 1-2 90%
13 _ Carcinoma in situ, high grade PIN 1-2 1-2 80%
14 _ Benign, atypical to well defined PIN 1 1 70%
15 _ PIN, tumor plus dysplasia 1 1 60%
16 _ No tumor, abscess 1 - 50%
17 _ Carcinoma in situ, locally invasive, high grade tumor 2 1 40%
18 _ Focal high grade PIN, carcinoma in situ, papillary hyperplasia 1-2 1-2 40%
19 _ Normal glandular morphology 1 1 30%
20 _ Typical hyperplasia, no tumor 1 1 20%
At the age of 20 weeks, β1pc-/- /TRAMP mice were subjected to IP injections of vehicle PP (-) or inhibitor SP (+), administered 
3 times/week for 10 weeks. Two hours after the first IP injection with either PP or SP, the lower pelvises of the mice were 
irradiated with a hypofractionated radiation regimen that consisted of 10 Gy fractions (total dose 50 Gy) administered for 
5 consecutive days. Mice were euthanized at 35 weeks of age and paraffin-embedded formalin-fixed prostate tissues were 
analyzed for FAK expression patterns. Histological features of 10 PP and 10 SP tissues are shown. “Percentage positive areas” 
at x40 optical magnification represents the number of cytoplasmic and/or nuclear FAK-positive regions over ten independent 
areas in each specimen analyzed. An optical region of a sample that showed more than 50% of cells with positive FAK staining 
was scored as FAK positive; FAK expression was scored using a 1-3 arbitrary scale in the FAK intensity column. -, indicates 
undetectable levels.
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FAK expression patterns by immunohistochemistry. Ten 
specimens in the PP and SP cohorts were studied for FAK 
intensity and scored. Our data indicate that SP-treated 
specimens show relatively higher FAK intensity and 
enhanced nuclear localization in comparison to the PP-
control cohort (Table 1 and Figure 5). These data highlight 
the role of β1 and JNK signaling in FAK regulation and 
strongly suggest a role for FAK in β1-dependent radiation 
resistance of prostate cancer. 
JnK inhibition in vivo fails to enhance FAK/AKT 
signaling upon irradiation in β1wt /trAMP mice 
Since JNK inhibition leads to the induction of FAK 
signaling in β1pc-/- /TRAMP prostate tumors, we assessed 
the FAK profile in β1wt /TRAMP prostate tissues. β1 
integrins are known to regulate FAK signaling [4] and we 
have previously demonstrated that β1 integrins suppress 
radiation-induced JNK signaling in prostate cancer 
[3]. Consistent with a dominant role of β1 integrins in 
suppressing JNK1 activation in β1wt /TRAMP mice, 
JNK inhibition in β1wt /TRAMP prostate tissues does not 
enhance FAK signaling (Figure 6A); we also observe that 
JNK inhibition in β1wt /TRAMP prostate tissues does not 
enhance AKT signaling. Conversely, our results indicate 
that JNK-inhibition dependent FAK up-regulation in 
prostate tumors selectively occurs in the absence of 
β1 integrins. We also investigated the expression of a 
neuroendocrine marker, chromogranin, in β1pc-/- and β1wt 
/TRAMP prostate tissues. Chromogranin expression is 
detected in both β1pc-/- and β1wt tissues regardless of JNK 
inhibition implying that β1, JNK or FAK signaling does 
not influence chromogranin expression in our model 
(Figure 6B).
β1 integrins regulate IGF-IR expression to 
enhance prostate cancer cell proliferation
We have previously reported that β1 integrin 
expression is regulated by IGF-IR, a receptor known 
Figure 3: JNK signaling is crucial for radiation-
dependent tumor suppression in the absence of β1 
integrins. A. Schematic representation showing that the 
effect of radiation is offset by JNK inhibition in β1pc-/-/TRAMP 
mice (upper panel). In contrast, the effect of radiation persists 
in SP600125-treated β1wt /TRAMP mice (lower panel). b. 
Immunoblot analysis shows the total and JNKpT183, pY185 levels in 
irradiated prostate tissues of β1pc-/- / TRAMP mice treated as in 
Figure 1. 
Figure 4: Tumor growth upon irradiation and JNK 
inhibition in β1pc-/-/trAMP mice is associated with 
enhanced FAK signaling. A. Induction of FAK expression 
and phosphorylation in prostate tumors from β1pc-/- /TRAMP 
mice. Immunoblot analysis of prostate tissues from β1pc-/- /
TRAMP mice treated as described in Figure 1. Prostate tissues 
were snap frozen. Tissues were homogenized and lysates 
analyzed by SDS-PAGE using Abs against FAKpY397 and total 
FAK. ERK1/2 was used as a loading control. b. Immunoblotting 
analysis of prostate tissues from β1pc-/- /TRAMP mice showing 
AKTpS473 and total AKT in prostate tissues as described above in 
Figure 4A. ERK1/2 was used as a loading control. 
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Figure 5: Irradiation coupled with JNK inhibition in β1pc-/- /TRAMP mice leads to increased levels of nuclear FAK in 
tumor cells. FAK expression profile in paraffin-embedded tissue sections from irradiated and SP600125-treated β1pc-/- /TRAMP mice are 
shown. Ten specimens in control PPCES and SP600125-treated cohorts were analyzed. Representative expression profiles are shown here. 
Scale bar 50 µm. 
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to promote resistance to radiation, and that abrogation 
of IGF-IR in prostate cancer cells leads to the loss of 
β1 integrins by proteasomal degradation [25]. Here we 
investigate whether β1 integrins affect IGF-IR expression. 
LNCaP cells were transiently transfected with β1-pcDNA 
together with control or IGF-IR siRNA to evaluate the 
expression of IGF-IR. Our results demonstrate that over-
expression of β1 leads to the up-regulation of IGF-IR 
(Figure 7A). However, IGF-IR down-regulation eliminates 
exogenous increase in β1 protein levels suggesting that 
the stability of β1 is dependent on IGF-IR, reinforcing our 
previous observation that in the absence of IGF-IR, β1 
is rapidly metabolized through proteasomal degradation. 
Both IGF-IR and β1 receptors seem to co-exist in a 
functional complex and stabilize each other’s expression in 
cancer cells. As shown in Figure 7B, exogenous induction 
of β1 significantly promotes cancer cell proliferation. 
Concurrent IGF-IR down-regulation reduces β1 levels 
Figure 7: β1 integrins promote cancer cell proliferation 
by regulating the expression of IGF-IR. A. Exogenous 
β1 induction leads to the up-regulation of IGF-IR expression. 
LNCaP cells were transiently transfected with either pBJ1 or 
β1-pBJ1 constructs, together with control or IGF-IR siRNA; 
48 hours later, cell lysates were analyzed by immunoblotting 
analysis for expression of the β1 integrin subunit and IGF-IR. 
AKT was used as a loading control. b. Exogenous β1 induction 
enhances cancer cell proliferation, which is blocked by IGF-
IR knockdown. LNCaP cells transfected as in Figure 7A were 
replated in equal numbers in culture dishes and allowed to grow 
for either 3 or 6 days followed by live cell counting. Each assay 
was performed in triplicate and asterisk signs represent statistical 
significance.
Figure 6: FAK/AKT signaling is not altered upon lower 
pelvis irradiation and JNK inhibition in β1wt /trAMP 
mice. A. Immunoblot analysis of prostate tissues from β1wt /
TRAMP mice treated as described in Figure 1. Frozen tissues 
were homogenized and lysates analyzed by SDS-PAGE using 
antibodies against total FAK, FAKpY397, total AKT and AKTpS473. 
ERK1/2 was used as a loading control. b. Neuroendocrine 
differentiation in response to irradiation and JNK inhibition in 
either β1pc-/- /TRAMP or β1wt /TRAMP prostate tissues. Number 
of mice analyzed: PPCES group β1pc-/- /TRAMP, n =  5; SP600125 
group β1pc-/- /TRAMP, n = 3; PPCES group β1wt /TRAMP, n = 3 
and SP600125 group β1wt /TRAMP, n = 3. Representative images 
reflecting the expression profile of chromogranin in β1pc-/- or β1wt 
TRAMP mice. Prostate tissues from β1pc-/- or β1wt /TRAMP mice 
treated as in Figure 1A above were fixed; sections were stained 
with a chromogranin Ab and processed for immunofluorescence. 
Counterstaining was done with DAPI not shown and expression 
profiles were studied by confocal microscopy. Scale bar 100 µm. 
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and thus significantly stalls cell proliferation suggesting 
that β1 functions are intrinsically dependent on IGF-
IR expression in prostate cancer cells. Thus, it could be 
speculated that both IGF-IR and β1 receptors concertedly 
modulate JNK signaling in response to radiation. 
dIscussIon
Using a novel hypofractionated radiation schedule 
that effectively blocks prostate tumor growth in TRAMP 
mice, we show that blocking JNK signaling using a JNK1, 
2 and 3 inhibitor (SP600125), counteracts the effects of 
therapeutic radiation and leads to tumor growth and 
progression, in a β1 integrin-dependent manner. 
Here we have tested a hypofractionated radiation 
scheme where a 50 Gy total dose of radiation was 
administered in 10 Gy fractions for 5 consecutive days, 
to approximate the hypofractionated approach in patients. 
This radiation schedule effectively suppresses tumor 
growth in β1wt mice and also in β1pc-/- mice which carry 
a conditional ablation of β1 integrins in the prostatic 
epithelium. However, inhibition of JNK phosphorylation 
negates the therapeutic effect of hypofractionated radiation 
in β1pc-/- /TRAMP but not β1wt /TRAMP mice. This is 
consistent with the notion that β1 integrin-dependent 
signaling determines the functional role of JNK as it 
relates to radiation response of the prostate epithelium. 
Our study delineates a JNK-mediated signaling 
pathway, which modulates tumor growth upon irradiation 
in a differential manner dependent on β1 expression. 
It is widely accepted that ionizing radiation activates 
multiple signal transduction pathways, including the 
JNK/SAPK cascade, which transduce death signals from 
the cell membrane to the nucleus. Since β1 integrins 
suppress JNK activation induced by radiation [3], SP 
treatment, as expected, did not affect radiation-induced 
tumor suppression in β1wt mice. Our results are in contrast 
with a previous report where inhibition of β1 integrins 
in head and neck carcinoma cells was reported to be 
associated with down-regulation of JNK signaling leading 
to radiosensitization [4]. However, there is substantial 
evidence demonstrating a pro-apoptotic role of JNK in 
response to radiation [26-29], which is consistent with our 
results. Although integrin interaction with the cytoskeleton 
is likely to mediate JNK activation, the association of β1 
with the cytoskeletal protein, filamin A [30] is not likely 
to explain our results since filamin A binds stress signaling 
kinases MKK4 and MKK7 and is known to enhance JNK 
activation [31] whereas β1 integrins suppress radiation-
dependent JNK signaling. 
A unique feature of irradiated and SP-treated β1pc-/- 
tumors is the up-regulation of FAK expression and auto-
phosphorylation which is not observed in β1pc-/- tissues 
from mice with functional JNK signaling or in β1wt tissues 
where JNK is inhibited. FAK auto-phosphorylation at 
tyrosine 397 (FAKpY397) exposes a site for Src, which leads 
to Src-dependent phosphorylation of FAK at tyrosines 
576 (FAKpY576) and 577 (FAKpY577) leading to maximal 
adhesion-induced FAK activation [32]. FAK expression 
has been reported to be enhanced in all stages of prostate 
tumorigenesis, to regulate anti-tumor immunity and 
integrin-dependent radioresistance [33-36]. Recently, 
nuclear FAK was reported to regulate immunomodulatory 
functions and inhibit anti-tumor immunity in cancerous 
squamous epithelial cells by regulating chemokine/
cytokine and ligand receptor networks [36], which is 
consistent with our results. FAK activity has further been 
implicated in DNA damage induced NF-kB activation 
and production of cytokines from endothelial cells 
leading to chemoresistance [37]. Similarly, β1 integrin-
dependent FAK signaling was reported to elicit faster cell 
attachment rates and reduced adhesion strength in taxol-
resistant ovarian cancer cells [38]. The authors report that 
adhesion strength is dependent on FAK. Besides, faster 
attachment rates and reduced adhesion strength, in these 
cells, correlate with increased β1 integrin expression 
and decreased focal adhesion formation, respectively. In 
addition, drug-tolerant microenvironments are known 
to be correlated with high β1 integrin/FAK signaling 
in melanoma cells [39]. Our data indicating high FAK 
expression and phosphorylation associated with tumor 
progression upon radiation, are consistent with these 
studies and collectively highlight a central role of FAK in 
therapeutic resistance. 
Activation of AKT has been reported earlier as an 
important predictor of the probability of PSA failure and a 
marker of clinically aggressive prostate cancer [40]. There 
is a significant interest in developing effective strategies 
to target this pathway [41]. In our studies, however, AKT 
activation in irradiated prostate tissues does not change 
upon JNK inhibition ruling out a significant functional 
contribution of JNK-dependent AKT activation in 
prostate cancer development in SP-treated β1pc-/- TRAMP 
mice. Finally, although sustained FAK expression and 
activity have been reported to be essential for androgen-
independent formation of neuroendocrine carcinoma 
[23], we observe significant chromogranin expression in 
TRAMP tissues that is not altered by either JNK inhibition 
or β1 abrogation. 
 Furthermore, our earlier report showed that 
abrogation of IGF-IR in prostate cancer cells enhances the 
sensitivity to radiation in a clonogenic assay [25]. Here 
we show that β1 integrins promote cell proliferation partly 
by enhancing the expression of IGF-IR underscoring 
the importance of β1/IGF-IR functional synergy. Using 
in vitro model systems of prostate cancer we have 
demonstrated a functional crosstalk between β1 integrins 
and IGF-IR and shown that these two vital receptors 
regulate each others’ expression [25]. In the present 
report, we further demonstrate that exogenous β1 integrins 
Oncotarget52627www.impactjournals.com/oncotarget
up-regulate IGF-IR expression leading to enhanced 
cell proliferation. This is consistent with our previous 
findings where abrogation of IGF-IR led to reduced 
β1 levels via proteasomal degradation and enhanced 
radiation sensitivity of prostate cancer cells [3, 25]. The 
identification of aberrant signaling pathways broaden the 
current concept of radiation sensitivity in exploring multi-
targeting molecular agents and aid in the development of 
novel therapeutic approaches.
In summary, we demonstrate that inhibition of 
JNK reactivates the growth of irradiated tumors, in a 
differential manner that depends on β1 integrins, and 
promotes FAK expression and activity. These findings 
have implications for the future design of combination 
therapies encompassing ionizing radiation and signal 
transduction modifiers.
MAterIAls And MetHods
reagents and antibodies
SP600125 (SP) was purchased from LC 
Laboratories. Murine monoclonal (m) antibodies 
(Abs) against the following antigens were used: human 
β1, TS2/16 (ATCC); β1, clone-18; JNK1/JNK2 (BD 
Pharmingen); c-Src (Cell Signaling). Rabbit polyclonal 
Abs against the following antigens were used: IGF-IR 
(IGF-IR-β sc713); AKT; FAK; ERK1/2 (Santa Cruz); 
chromogranin (Invitrogen); FAKpY397, SrcpY416, JNKpT183, 
pY185, AKTpS473 and AKT (Cell Signaling). Non-immune 
rabbit IgG was purchased from Pierce. Alexa Fluor 488 
goat anti-rabbit IgG was purchased from Invitrogen. 
cell lines
LNCaP prostate cancer cells were purchased from 
ATCC and authenticated by the supplier. Cells were grown 
at 37°C and 5% CO2 in RPMI-1640 supplemented with 
5% FBS and 1%, each of sodium pyruvate, HEPES and 
non-essential amino acids. 
Mice
TRAMP mice carrying conditional ablation of β1 
(β1pc-/- /TRAMP) and those expressing wild type β1 (β1wt 
/TRAMP) were generated as described earlier [3]. Care 
of animals was in compliance with standards established 
by the office of laboratory animal welfare, Department 
of Health and Human Services at NIH. Experimental 
protocols were approved by the Institutional Animal Care 
and Use Committee, Thomas Jefferson University. 
SP injection and hypofractionated irradiation
SP was suspended in PP mixture comprising of 30% 
PEG-400, 20% polypropylene glycol, 15% cremophor, 
5% ethanol and 30% saline [12]. At the age of 20 weeks, 
β1pc-/- /TRAMP and β1wt /TRAMP mice were subjected to 
IP injections of vehicle PP (150µl) or inhibitor SP (30mg/
kg), administered 3 times / week for 10 weeks. Two hours 
after the first IP injection with either PP or SP, the lower 
pelvis of the mice was irradiated with 10 Gy radiation as a 
part of hypofractionated radiation regimen that consisted 
of 10 Gy fractions (total dose 50 Gy) administered for 
5 consecutive days. Animals were anesthetized with 
Ketamine-Xylazine-Acepromazine mixture (0.125 
ml/100g of body weight),(Ketamine, 80 mg/ml; Xylazine 
5 mg/ml; Acepromazine, 1.6 mg/ml) providing 25-30 
minutes sedation, prior to being placed in malleable lead 
shielding. The shield ensures that upper body including 
upper gastrointestinal tract is protected. Lower pelvises 
of mice were irradiated using a PanTak 310keV X-ray 
machine at 0.25mm Cu plus 1mm Al added filtration, 
at 125 cGy/min. Mice were euthanized at the age of 35 
weeks for studying tumor progression. Prostate isolation 
was performed using a dissection stereomicroscope 
SZX10 (Olympus). Prostate tissues were weighed and 
fixed for histopathologic analysis. A small amount of 
tissue was frozen for immunoblotting analysis. Lungs, 
liver and lymph nodes were fixed for studying metastasis. 
Immunohistochemistry (IHc)
IHC analysis was carried out as reported earlier [3]. 
Lungs, liver and lymph nodes from mice were processed 
in the same manner and stained with H&E for studying 
metastasis. Histological analysis of prostate and metastases 
was performed by Dr. Peter McCue. Total FAK levels 
were analyzed in paraffin-embedded formalin-fixed tumor 
sections of β1pc-/- /TRAMP mice by IHC as reported earlier 
for other molecules [42], with the exception of using 
biotin-streptavidin-amplified peroxidase immunodetection 
system with DAB kit (Invitrogen). 
Immunofluorescence and confocal microscopy
Immunofluorescence was carried out as described 
earlier [43]. Staining with an Ab to chromogranin was 
performed by incubation of tissue samples with primary 
Abs (1:100) for 1 hour at RT, followed by incubation with 
Alexa Fluor 488 goat rabbit IgG (1:250) for 20 minutes 
at RT. 
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Transient transfection
Transfection of cells with siRNA oligonucleotides 
(Thermo Scientific) was performed as previously described 
[44]. To -regulate IGF-IR, the sequences of sense strands 
of duplex siRNAs used are as follows: IGF-IR-siRNA: 
5’-CGACUAUCAGCAGCUGAAGUUdTdT-3’; control 
 IGF-IR-siRNA: 5’-GAAGUCGACGACUAUCAGCU 
UdTdT-3’ [25].
Cell proliferation assay
LNCaP cells were transfected with either empty 
vector pBJ1 or recombinant β1-pBJ1 plasmid together 
with either control siRNA or IGF-IR siRNA [25]. Cells 
were trypsinized 24 hours after transfection and plated in 
triplicate sets in fresh growth medium at 1.5×104 cells/well 
in 6-well plates. Cells for growth assay were harvested 
at day 3 and day 6 after plating. Cells were trypsinized 
and pellets resuspended in 500µl of PBS followed by live-
cell counting using hemocytometer. In parallel, cells were 
plated in 10 cm dishes to evaluate expression changes by 
immunoblotting. 
Immunoblotting (Ib)
IB was performed on tumor and cell lysates as 
reported earlier [25, 43]. 
statistical analysis
Wilcoxon-Mann-Whitney test was used to compare 
the median tumor weight. Interquartile range and 
individual data points were plotted to compare the tumor 
mass between vehicle and SP-treated β1pc-/- /TRAMP and 
β1wt /TRAMP groups. Statistical analysis for proliferation 
assay was performed using two-tailed t-test. 
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